If the drugs are directly both improving weight reduction and cancer reduction, then we need to double down. Ganta wonders the same thing about the drugs apparent positive effects on several conditions, from dementia to sleep apnea: Is it that obesity is causing or contributing to the problem [and that weight loss is causing the improvement], or is the medication directly having an impact through a different mechanism? She hopes there will be more research to parse this out in the years to come
doi:10.1146/annurev-nutr-120420-021719
An Endocrine Society study presented at ENDO 2025 found that anti-obesity medications, including semaglutide and tirzepatide, can normalize testosterone levels in men
A 12mg dose = 1.2mL, which requires two draws
That wide reach can sound exaggerated at first, but the mechanism story is stronger than most people expect
The article suggests tracking biomarkers across 8 to 12 weeks of consistent effort